Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Ben A. Blomberg, MD, Hendrik W. Van Deventer, MD, Stuart Gold, MD, Katarzyna Joanna Jamieson, MD, Joshua F. Zeidner, MD, Benyam Muluneh, PharmD, Dominic Moore, PhD, Matthew C. Foster, MD

Blood (2015) 126 (23): 4919.

https://doi.org/10.1182/blood.V126.23.4919.4919

Published: 2015

Journal Articles

Heterogeneity of Adult Acute Lymphoblastic Leukemia Among Racial and Ethnic Minorities in a Diverse Single-Institution Population: Inferior Progression-Free Survival Among Hispanics and Patients Not Completing Maintenance Chemotherapy

Matthew C Foster, MD, Steven I. Park, MD, Dominic Moore, PhD, Andrew Dodd, Nathan Barr, Thomas C. Shea, MD

Blood (2012) 120 (21): 4291.

https://doi.org/10.1182/blood.V120.21.4291.4291

Published: 2012

Journal Articles

The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy

Steven I. Park, MD, Amy S. Lucas, MD, Michael Kingberg, BSc, Dominic Moore, PhD, Michael Chiu, MS, Anne M.D. Misher, BSc, Janelle Hoskins, PhD, Cherie H. Dunphy, MD, Howard L. McLeod, Pharm D, Kristy L. Richards, PhD, MD

Blood (2011) 118 (21): 89.

https://doi.org/10.1182/blood.V118.21.89.89

Published: 2011

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, M.D., Cristina Gasparetto, MD, Keren Osman, MD, Kristy Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, OCN, Jennifer MacLean, RN, Diane Winans, Dominic Moore, PhD, John Strader, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2010) 116 (21): 1955.

https://doi.org/10.1182/blood.V116.21.1955.1955

Published: 2010

Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD

Blood (2007) 110 (11): 4940.

https://doi.org/10.1182/blood.V110.11.4940.4940

Published: 2007

NARROW

A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Heterogeneity of Adult Acute Lymphoblastic Leukemia Among Racial and Ethnic Minorities in a Diverse Single-Institution Population: Inferior Progression-Free Survival Among Hispanics and Patients Not Completing Maintenance Chemotherapy

The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Heterogeneity of Adult Acute Lymphoblastic Leukemia Among Racial and Ethnic Minorities in a Diverse Single-Institution Population: Inferior Progression-Free Survival Among Hispanics and Patients Not Completing Maintenance Chemotherapy

The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only